Cargando…
Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members
BACKGROUND: Due to the low mutational testing rate in patients with Gastrointestinal Stromal Tumors (GIST), The Life Raft Group (LRG), a non-profit organization that provides support, advocacy and conducts research for patients with GIST, analyzed various factors that may have an impact on patients’...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667594/ https://www.ncbi.nlm.nih.gov/pubmed/36380293 http://dx.doi.org/10.1186/s12876-022-02548-8 |
_version_ | 1784831754124656640 |
---|---|
author | Montoya, Denisse Call, Jerry W. Eshak, Jennily Knox, Pete Luedke, Maeven Kaur, Sahibjeet Rothschild, Sara Garland, Mary Scherzer, Norman J. |
author_facet | Montoya, Denisse Call, Jerry W. Eshak, Jennily Knox, Pete Luedke, Maeven Kaur, Sahibjeet Rothschild, Sara Garland, Mary Scherzer, Norman J. |
author_sort | Montoya, Denisse |
collection | PubMed |
description | BACKGROUND: Due to the low mutational testing rate in patients with Gastrointestinal Stromal Tumors (GIST), The Life Raft Group (LRG), a non-profit organization that provides support, advocacy and conducts research for patients with GIST, analyzed various factors that may have an impact on patients’ ability to receive mutational testing. METHODS: A survey about mutational testing for patients with GIST or their caregivers, was conducted in June 2020. The survey, sent to 1004 GIST patients and caregivers through email, was promoted through social media with instructions to contact the LRG to participate. The survey was designed by the LRG Patient Registry Department. Members of the LRG, regardless of Patient Registry status, were eligible to participate. RESULTS: A total of 295 patients/caregivers participated in this study (response rate: 29.4%). The percentage of patients who indicated they had received mutational testing was much higher in this survey (80%) than in the general GIST community (26.7%). Several reasons were cited for having a test, including: “My doctor ordered/suggested that I have it done” (54%); “The Life Raft Group advised/suggested I have it done” (25%); “I asked my doctor to have it done” (22%); “I had it done as part of a clinical trial” (5%); “I am not sure” (3%) and “Other” (14%). Mutational testing resulted in a treatment change in 25% of cases. Patients were able to select more than one option when completing this question resulting in a percentage greater than 100. CONCLUSIONS: The LRG membership is voluntary and proactive; patients who join are more likely to participate in surveys and mutational testing, as well as more likely to have a GIST specialist. Mutational testing can influence understanding of a patient’s GIST and the treatment best suited to each case. These are extremely important findings, as it helps ensure that patients are on the proper treatment, which should lead to better outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-022-02548-8. |
format | Online Article Text |
id | pubmed-9667594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96675942022-11-17 Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members Montoya, Denisse Call, Jerry W. Eshak, Jennily Knox, Pete Luedke, Maeven Kaur, Sahibjeet Rothschild, Sara Garland, Mary Scherzer, Norman J. BMC Gastroenterol Research BACKGROUND: Due to the low mutational testing rate in patients with Gastrointestinal Stromal Tumors (GIST), The Life Raft Group (LRG), a non-profit organization that provides support, advocacy and conducts research for patients with GIST, analyzed various factors that may have an impact on patients’ ability to receive mutational testing. METHODS: A survey about mutational testing for patients with GIST or their caregivers, was conducted in June 2020. The survey, sent to 1004 GIST patients and caregivers through email, was promoted through social media with instructions to contact the LRG to participate. The survey was designed by the LRG Patient Registry Department. Members of the LRG, regardless of Patient Registry status, were eligible to participate. RESULTS: A total of 295 patients/caregivers participated in this study (response rate: 29.4%). The percentage of patients who indicated they had received mutational testing was much higher in this survey (80%) than in the general GIST community (26.7%). Several reasons were cited for having a test, including: “My doctor ordered/suggested that I have it done” (54%); “The Life Raft Group advised/suggested I have it done” (25%); “I asked my doctor to have it done” (22%); “I had it done as part of a clinical trial” (5%); “I am not sure” (3%) and “Other” (14%). Mutational testing resulted in a treatment change in 25% of cases. Patients were able to select more than one option when completing this question resulting in a percentage greater than 100. CONCLUSIONS: The LRG membership is voluntary and proactive; patients who join are more likely to participate in surveys and mutational testing, as well as more likely to have a GIST specialist. Mutational testing can influence understanding of a patient’s GIST and the treatment best suited to each case. These are extremely important findings, as it helps ensure that patients are on the proper treatment, which should lead to better outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-022-02548-8. BioMed Central 2022-11-15 /pmc/articles/PMC9667594/ /pubmed/36380293 http://dx.doi.org/10.1186/s12876-022-02548-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Montoya, Denisse Call, Jerry W. Eshak, Jennily Knox, Pete Luedke, Maeven Kaur, Sahibjeet Rothschild, Sara Garland, Mary Scherzer, Norman J. Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members |
title | Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members |
title_full | Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members |
title_fullStr | Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members |
title_full_unstemmed | Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members |
title_short | Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members |
title_sort | barriers to mutational testing in patients with gastrointestinal stromal tumors (gist) – a survey of life raft group members |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667594/ https://www.ncbi.nlm.nih.gov/pubmed/36380293 http://dx.doi.org/10.1186/s12876-022-02548-8 |
work_keys_str_mv | AT montoyadenisse barrierstomutationaltestinginpatientswithgastrointestinalstromaltumorsgistasurveyofliferaftgroupmembers AT calljerryw barrierstomutationaltestinginpatientswithgastrointestinalstromaltumorsgistasurveyofliferaftgroupmembers AT eshakjennily barrierstomutationaltestinginpatientswithgastrointestinalstromaltumorsgistasurveyofliferaftgroupmembers AT knoxpete barrierstomutationaltestinginpatientswithgastrointestinalstromaltumorsgistasurveyofliferaftgroupmembers AT luedkemaeven barrierstomutationaltestinginpatientswithgastrointestinalstromaltumorsgistasurveyofliferaftgroupmembers AT kaursahibjeet barrierstomutationaltestinginpatientswithgastrointestinalstromaltumorsgistasurveyofliferaftgroupmembers AT rothschildsara barrierstomutationaltestinginpatientswithgastrointestinalstromaltumorsgistasurveyofliferaftgroupmembers AT garlandmary barrierstomutationaltestinginpatientswithgastrointestinalstromaltumorsgistasurveyofliferaftgroupmembers AT scherzernormanj barrierstomutationaltestinginpatientswithgastrointestinalstromaltumorsgistasurveyofliferaftgroupmembers |